MOTS-c + NAD+: Build More Mitochondria, Then Fuel Them
A focused two-lever protocol — MOTS-c drives mitochondrial biogenesis through AMPK and PGC-1α, while NAD+ precursors restore the coenzyme that powers ATP production and feeds the sirtuins. More power plants, more fuel to run them.
What's in the Stack
MOTS-c is a 16-amino acid mitochondrial-derived peptide that activates AMPK and PGC-1α-related pathways, signaling cells to build entirely new mitochondria. It behaves as an exercise mimetic — in humans, muscle MOTS-c rises roughly 11.9-fold after a single bout of exercise (Reynolds et al., Nature Communications, 2021).
NAD+ is the coenzyme that lets mitochondria turn nutrients into ATP, and the substrate that powers sirtuins and PARP-driven DNA repair. NAD+ levels fall with age. Oral NMN/NR precursors measurably raise blood NAD+ — Yoshino et al. (2018) reported safe elevation in human trials at doses up to 1200 mg/day.
The two levers are complementary, not redundant. MOTS-c builds more mitochondria; NAD+ supplies the coenzyme those mitochondria and their sirtuins actually run on. Building more power plants is of limited use if the fuel cofactor is depleted — and vice versa. The pairing targets both supply and capacity.
Sirtuins (SIRT1–7) are NAD+-dependent enzymes governing metabolism, inflammation, and stress response. Imai & Guarente (2014) established the NAD+/sirtuin axis as central to aging. Keeping NAD+ available is what lets these enzymes do their regulatory work as biogenesis ramps up.
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- This is a focused two-compound protocol — MOTS-c for mitochondrial biogenesis plus NAD+ precursors for fuel and sirtuin substrate. It is the simpler sibling of our three-compound mitochondrial-energy-stack.
- MOTS-c is a 16-amino acid mitochondrial-derived peptide that activates AMPK and reversed diet-induced obesity and insulin resistance in mice (Lee C et al., Cell Metabolism, 2015, PMID 25738459).
- In humans, skeletal-muscle MOTS-c rises roughly 11.9-fold after a single bout of exercise, and MOTS-c roughly doubled treadmill capacity in aged mice (Reynolds et al., Nature Communications, 2021, PMID 33547290).
- Oral NMN/NR precursors measurably raise blood NAD+; human trials showed safe elevation at up to 1200 mg NMN/day (Yoshino et al., 2018), with no serious adverse events across completed trials (Khatri et al., 2025 systematic review).
- The NAD+/sirtuin axis is central to aging biology (Imai & Guarente, 2014) — NAD+ is the substrate sirtuins and PARP repair enzymes depend on.
- The two compounds are mechanistically complementary: MOTS-c increases mitochondrial number/capacity, NAD+ supplies the coenzyme that capacity runs on.
- Neither MOTS-c nor NAD+ precursors are FDA-approved drugs for energy, longevity, or performance. They are research compounds and supplements, not approved treatments.
- There is no clinical trial of this specific two-compound combination. Mechanistic complementarity is plausible, but the synergy itself is unproven in humans.
- NAD+ benefits beyond raising blood NAD+ are mixed: muscle mass/strength effects were non-significant in meta-analysis and performance gains were modest and inconsistent (Khatri 2025).
- Much of the strongest MOTS-c data is from mice (obesity reversal, doubled running). Human MOTS-c administration data is far thinner than the exercise-induction data.
- Healthy, fit individuals with normal baseline NAD+ may see little measurable benefit from boosting; the largest effects appear in older or metabolically compromised people.
- Lifespan extension and reversal of biological aging in humans are NOT demonstrated for either compound.
Frequently Asked Questions
What is the MOTS-c + NAD+ stack?
It is a focused two-compound cellular-energy protocol. MOTS-c, a mitochondrial-derived peptide, signals cells to build more mitochondria via AMPK and PGC-1α. NAD+ precursors (NMN or NR) restore the coenzyme those mitochondria use to make ATP and that powers sirtuins. One lever builds capacity, the other supplies fuel.
How is this different from the mitochondrial energy stack?
The three-layer mitochondrial-energy-stack adds a third compound, 5-Amino-1MQ, an NNMT inhibitor that slows NAD+ breakdown to make supplementation more durable. This page is deliberately the simpler two-lever version — biogenesis plus fuel — for people who want to start before adding a preservation layer. See our mitochondrial-energy-stack page for the full three-compound build.
What doses are used in research?
MOTS-c research protocols commonly use 5–10 mg subcutaneous, dosed 2–3 times per week. NMN is typically 250–500 mg daily oral to start, with human trials using up to 1200 mg/day. Some protocols add periodic clinic-administered IV NAD+ for higher bioavailability. Always start low and titrate over 2–4 weeks.
Does the evidence support this combination?
The individual compounds have real data: MOTS-c rises 11.9-fold in human muscle after exercise (Reynolds 2021) and reversed obesity in mice (Lee 2015); NMN safely raises blood NAD+ in humans (Yoshino 2018; Khatri 2025 review). But there is no trial of the two combined, so the pairing is mechanistically rational rather than clinically proven.
Is this stack safe?
The 2025 systematic review (Khatri et al.) found no serious adverse events across completed human NAD+ precursor trials, supporting a clean short-term safety profile for NMN/NR. MOTS-c human safety data is thinner. Neither is an approved drug, and the combination has not been studied for safety together. This is educational information, not medical advice.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
MOTS-c is a research peptide and NAD+ precursors (NMN/NR) are supplements; neither is an FDA-approved treatment for energy, longevity, or performance. Nothing here is a recommendation to obtain or self-administer any compound.
No clinical trial has studied this two-compound combination. All figures are cited from peer-reviewed work on the individual compounds (Lee et al., Cell Metabolism 2015, PMID 25738459; Reynolds et al., Nature Communications 2021, PMID 33547290; Yoshino et al., 2018; Imai & Guarente, 2014; Khatri et al., 2025 systematic review). Consult a qualified healthcare provider before any metabolic intervention.